



Revision of Precautions

Caspofungin Acetate

April 20, 2017

Non-proprietary name

Caspofungin acetate

Safety measure

Precautions should be revised in the package insert.

In the Clinically Significant Adverse Reactions subsection of the Adverse Reactions section, the following text should be added (underlined parts are revised):

Toxic epidermal necrolysis (TEN) and oculomucocutaneous syndrome (Stevens-Johnson syndrome): Toxic epidermal necrolysis and oculomucocutaneous syndrome may occur.
Patients should be carefully monitored. If any abnormalities are observed, administration of this drug should be discontinued and appropriate measures should be taken.